This post was originally published on this site
https://www.washingtonpost.com/wp-apps/imrs.php?src=https://arc-anglerfish-washpost-prod-washpost.s3.amazonaws.com/public/7MNS3JBOWQI6ZML5TBOBQ3PDHA.jpg&w=1440
Anxious and bewildered, some drugmakers are reaching out to their lobbyists about how Robert Kennedy’s pending nomination will affect the Food and Drug Administration.